호흡기 치료제 시장 규모, 점유율, 성장 분석, 약제 클래스별, 질환 유형별, 투여 경로별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Respiratory Drugs Market Size, Share, and Growth Analysis, By Drug Class (Short-Acting Beta2-Agonists, Long-Acting Beta2-Agonists ), By Disease Type, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1755445
리서치사:SkyQuest
발행일:2025년 06월
페이지 정보:영문 197 Pages
라이선스 & 가격 (부가세 별도)
한글목차
호흡기 치료제 세계 시장 규모는 2023년에 37억 달러, 2024년 40억 1,000만 달러에서 2032년에는 77억 1,000만 달러로 성장하고, 예측 기간(2025-2032년) CAGR은 8.5%를 나타낼 전망입니다.
호흡기 치료제 시장은 전 세계 호흡기 질환의 급격한 증가를 배경으로 2025-2032년까지 크게 성장할 것으로 전망됩니다. 대기오염 증가, 알레르겐 노출 증가, 호흡기 질환에 대한 인식 증가 등의 치료 요인으로 인해 진단율과 치료율이 증가하고 있습니다. 고소득 국가에서는 만성폐쇄성폐질환(COPD)의 70% 이상이 흡연으로 인한 것이지만, 중저소득 국가에서는 30-40%이며, 가정 내 대기오염도 중요한 역할을 하고 있습니다. 흡연은 폐 기능에 장기적인 손상을 입히기 때문에 COPD, 폐암, 호흡기 감염과 같은 호흡기 질환의 주요 원인임에는 변함이 없습니다. 이는 이러한 일반적인 증상을 관리하기 위한 효과적인 호흡기 치료제가 시급히 필요하다는 것을 강조합니다.
목차
서론
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장 전제조건과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porter의 Five Forces 분석
주요 시장 인사이트
중요 성공 요인
경쟁 정도
주요 투자 기회
시장 생태계
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
호흡기 치료제 시장 규모 : 약제 클래스별&CAGR(2025-2032년)
시장 개요
단시간 작용형 β2 자극제(SABA)
장시간 작용형 β2 자극제(LABA)
흡입 코르티코스테로이드(ICS)
항콜린제
항히스타민제
혈관 확장제
병용약
기타
호흡기 치료제 시장 규모 : 질환 유형별&CAGR(2025-2032년)
시장 개요
천식
만성 기관지염
만성 폐쇄성 폐질환(COPD)
흉수
기타
호흡기 치료제 시장 규모 : 투여 경로별&CAGR(2025-2032년)
시장 개요
흡입
경장
비경구
호흡기 치료제 시장 규모 : 유통 채널별&CAGR(2025-2032년)
시장 개요
병원 약국
소매 약국
온라인 약국
호흡기 치료제 시장 규모&CAGR(2025-2032년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
주요 5개사 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 상세
제품 포트폴리오 분석
기업 부문별 점유율 분석
매출 전년대비 비교(2022-2024년)
주요 기업 개요
GlaxoSmithKline Plc(GSK)(영국)
AstraZeneca Plc(영국)
Boehringer Ingelheim International GmbH(독일)
Merck & Co., Inc.(미국)
Novartis AG(스위스)
F. Hoffmann-La Roche Ltd.(스위스)
Teva Pharmaceutical Industries Ltd.(이스라엘)
Sanofi(프랑스)
Pfizer Inc.(미국)
AbbVie Inc.(미국)
Vertex Pharmaceuticals Incorporated(미국)
Mylan Pharmaceuticals Inc.(미국)
Sun Pharmaceutical Industries Ltd.(인도)
Lupin Limited(인도)
Cipla Limited(인도)
Chiesi Farmaceutici S.p.A.(이탈리아)
Sumitomo Dainippon Pharma Co., Ltd.(일본)
Beximco Pharmaceuticals Ltd.(방글라데시)
Respirerx Pharmaceuticals Inc.(미국)
Viatris Inc.(미국)
결론과 제안
LSH
영문 목차
영문목차
Global Respiratory Drugs Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 4.01 billion in 2024 to USD 7.71 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032).
The respiratory drugs market is poised for significant growth between 2025 and 2032, driven by a surge in respiratory disorders globally. Factors such as rising air pollution, increased allergen exposure, and heightened awareness of respiratory diseases have led to greater diagnosis and treatment rates. In high-income countries, over 70% of Chronic Obstructive Pulmonary Disease (COPD) cases are attributed to tobacco smoking, while in low- and middle-income countries, this figure is 30-40%, with household air pollution also playing a critical role. Smoking remains a leading cause of respiratory issues, including COPD, lung cancer, and respiratory infections, as it inflicts long-term damage on lung function. This underscores the urgent need for effective respiratory therapies to manage these prevalent conditions.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Respiratory Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Respiratory Drugs Market Segments Analysis
Global Respiratory Drugs Market is segmented by Drug Class, Disease Type, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Short-Acting Beta2-Agonists (SABA), Long-Acting Beta2-Agonists (LABA), Inhaled Corticosteroids (ICS), Anticholinergics, Antihistamines, Vasodilators, Combination Drugs and Others. Based on Disease Type, the market is segmented into Asthma, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Pleural Effusion and Others. Based on Route of Administration, the market is segmented into Inhalation, Enteral and Parenteral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Respiratory Drugs Market
The Global Respiratory Drugs market is significantly driven by advancements in artificial intelligence, which are transforming the discovery process of new respiratory medications. By swiftly analyzing extensive datasets, AI technologies can pinpoint potential compounds and biological targets with remarkable speed and efficiency. Machine learning algorithms can effectively simulate the interactions between drug candidates and human biology, thereby streamlining the preclinical phase and accelerating overall development timelines. Notably, AI platforms such as BenevolentAI and Atomwise are being harnessed to create groundbreaking therapies for conditions like asthma and chronic obstructive pulmonary disease (COPD), empowering pharmaceutical companies to enhance innovation while minimizing research and development costs.
Restraints in the Global Respiratory Drugs Market
The Global Respiratory Drugs market faces certain constraints, particularly in the integration of artificial intelligence into drug development. This process demands a significant investment in computational infrastructure, skilled workforce, and ongoing software enhancements, which can be financially burdensome for smaller pharmaceutical firms or those operating in developing regions. Additionally, the challenge of incorporating AI tools into existing legacy systems often results in technical and logistical difficulties, hindering the progress of digital transformation within research and development efforts for respiratory medications. These factors collectively pose considerable obstacles to the advancement and efficiency of respiratory drug innovation in the market.
Market Trends of the Global Respiratory Drugs Market
The Global Respiratory Drugs market is increasingly influenced by the rise of AI-enabled smart inhalers, which are transforming respiratory care. These innovative devices, such as Propeller Health's inhaler sensors, track medication adherence, monitor symptoms, and offer real-time feedback to both patients and healthcare providers. By ensuring proper inhaler techniques and minimizing missed doses, these technologies enhance patient engagement and adherence to treatment protocols. Furthermore, the data generated facilitates personalized treatment plans, thereby improving clinical outcomes. As advancements in AI and digital health technology progress, the integration of smart inhalers is expected to drive substantial growth in the respiratory drugs sector, meeting the rising demand for more effective, personalized healthcare solutions.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Respiratory Drugs Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Short-Acting Beta2-Agonists (SABA)
Long-Acting Beta2-Agonists (LABA)
Inhaled Corticosteroids (ICS)
Anticholinergics
Antihistamines
Vasodilators
Combination Drugs
Others
Global Respiratory Drugs Market Size by Disease Type & CAGR (2025-2032)
Market Overview
Asthma
Chronic Bronchitis
Chronic Obstructive Pulmonary Disease (COPD)
Pleural Effusion
Others
Global Respiratory Drugs Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Inhalation
Enteral
Parenteral
Global Respiratory Drugs Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Respiratory Drugs Market Size & CAGR (2025-2032)
North America (Drug Class, Disease Type, Route of Administration, Distribution Channel)
US
Canada
Europe (Drug Class, Disease Type, Route of Administration, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Drug Class, Disease Type, Route of Administration, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Drug Class, Disease Type, Route of Administration, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Drug Class, Disease Type, Route of Administration, Distribution Channel)
